Hypercalcemia following discontinuation of denosumab therapy: A systematic review.

ABSTRACT: Denosumab is a monoclonal antibody that has been approved to treat osteoporosis, skeletal metastasis, and giant cell tumor of bone in skeletally mature patients. Due to its potential adverse effects on normal bone growth, its use has not yet been approved in skeletally immature patients; however, the use of this agent in such patients with overt or dysregulated bone resorptive conditions has been explored in recent years. While most studies have proven the effectiveness of denosumab in controlling the progression of various disorders in skeletally immature patients, they have also revealed that refractory hypercalcemia often follows the discontinuation of denosumab treatment, raising a concern over the use of this agent in these patients. Thus, this study was designed to better understand

SUBMITTER: Horiuchi K 

PROVIDER: S-EPMC8605220 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature